GPRC5D is highly expressed in malignant bone marrow plasma cells derived from CD138 + MM patients, while its expression independently of BCMA, making it a potential excellent target for multiple myeloma therapy [68]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.